Targeted release of budesonide in primary IgA nephropathy
- PMID: 38944524
- DOI: 10.1016/S0140-6736(24)00794-3
Targeted release of budesonide in primary IgA nephropathy
Comment in
-
Targeted release of budesonide in primary IgA nephropathy - Authors' reply.Lancet. 2024 Jun 29;403(10446):2786. doi: 10.1016/S0140-6736(24)00796-7. Lancet. 2024. PMID: 38944527 No abstract available.
Comment on
-
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.Lancet. 2023 Sep 9;402(10405):859-870. doi: 10.1016/S0140-6736(23)01554-4. Epub 2023 Aug 14. Lancet. 2023. PMID: 37591292 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous